To provide a more comprehensive assessment of RGS responses, we performed bulk RNA sequencing analysis on the YUMM3.3 tumors (RGS and vehicle treated), including tumor cells, stromal cells, and immune cells. This evidence concerns the gene PITX2 and neoplasm.